EUCTR2020-001175-32-GB
Active, not recruiting
Phase 1
Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated pain. - OpiCapone Effect on motor fluctuations and pAiN (OCEAN)
ConditionsParkinson's disease patients with wearing-off motor fluctuations andassociated pain.MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
DrugsOngentys
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Parkinson's disease patients with wearing-off motor fluctuations andassociated pain.
- Sponsor
- Bial - Portela & Ca, S.A.
- Enrollment
- 176
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion criteria at Visit 1 (Screening):
- •1\. Able to comprehend and willing to sign an informed consent form and to comply
- •with all aspects of the study.
- •2\. Male or female patients aged 30 years or older.
- •3\. Experiencing PD associated pain for at least 4 weeks prior to screening.
- •4\. Diagnosed with idiopathic PD according to the UK Parkinson’s Disease Society
- •Brain Bank Clinical Diagnostic Criteria (2006\) or according to MDS Clinical
- •Diagnostic Criteria (2015\).
- •5\. Disease severity Stages I\-III (modified Hoehn \& Yahr staging) at ON.
- •6\. Treated with 3 to 7 intakes per day of L\-dopa/DDCI (which may include a slow\-
Exclusion Criteria
- •1\. Non\-idiopathic PD (atypical parkinsonism, secondary \[acquired or symptomatic]
- •parkinsonism, Parkinson\-plus syndrome).
- •2\. Severe and/or unpredictable OFF periods, according to investigator judgement.
- •3\. Major/prominent non\-PD\-related pain (e.g. due to malignant disease).
- •4\. Treatment with prohibited medication: entacapone, tolcapone, monoamine oxidase
- •(MAO) inhibitors (except selegiline up to 10 mg/day in oral formulation or
- •1\.25 mg/day in buccal absorption formulation, rasagiline up to 1 mg/day or
- •safinamide up to 100 mg/day), or antiemetics with antidopaminergic action
- •(except domperidone) within the last 4 weeks before V1\.
- •5\. Previous or planned (during the entire study duration) L\-dopa/carbidopa
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Clinical study to investigate if Opicapone 50mg can reduce pain associated to Parkinson’s diseaseEUCTR2020-001175-32-PTBial - Portela & Ca, S.A.176
Active, not recruiting
Phase 1
Clinical study to investigate if Opicapone 50mg can reduce pain associated to Parkinson’s diseaseParkinson's disease patients with wearing-off motor fluctuations and associated pain.MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2020-001175-32-CZBial - Portela & Ca, S.A.176
Active, not recruiting
Phase 1
Clinical study to investigate if Opicapone 50mg can reduce pain associated to Parkinson’s diseaseParkinson's disease patients with wearing-off motor fluctuations and associated pain.MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2020-001175-32-PLBial - Portela & Ca, S.A.176
Completed
Phase 1
Randomized, double-blind, placebo-controlled, clinical trial with OSD-001 for skin lesions due to tuberous sclerosis complex.JPRN-UMIN000012420Department of Dermatology Graduate School of Medicine, Osaka University36
Active, not recruiting
Phase 1
Clinical study to investigate if Opicapone 50mg can reduce pain associated to Parkinson's diseaseParkinson's disease patients with wearing-off motor fluctuations and associated pain.MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2020-001175-32-ITBIAL-Portela & Ca, S.A.176